{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:19:56Z","timestamp":1790612396004,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.mehy.2020.109776","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:42:51Z","timestamp":1587555771000},"page":"109776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?"],"prefix":"10.1016","volume":"140","author":[{"given":"Elena","family":"Carboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.109776_b0005","doi-asserted-by":"crossref","unstructured":"Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020 Mar 23. pii: AAC.00483-20. doi:10.1128\/AAC.00483-20.","DOI":"10.1128\/AAC.00483-20"},{"key":"10.1016\/j.mehy.2020.109776_b0010","doi-asserted-by":"crossref","unstructured":"Meng L, Qiu H, Wan L, et al. Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience [published online ahead of print, 2020 Mar 26].Anesthesiology. 2020;10.1097\/ALN.0000000000003296. doi:10.1097\/ALN.0000000000003296.","DOI":"10.1097\/ALN.0000000000003296"},{"issue":"1","key":"10.1016\/j.mehy.2020.109776_b0015","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res."},{"key":"10.1016\/j.mehy.2020.109776_b0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-020-01626-9","article-title":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China","author":"Li","year":"2020","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.mehy.2020.109776_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.mehy.2020.109776_b0030","doi-asserted-by":"crossref","unstructured":"Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12. pii: S1201-9712(20)30136-3. doi: 10.1016\/j.ijid.2020.03.017.","DOI":"10.1016\/j.ijid.2020.03.017"},{"key":"10.1016\/j.mehy.2020.109776_b0035","first-page":"E004","article-title":"Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV","volume":"48","author":"Peng","year":"2020","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.mehy.2020.109776_b0040","article-title":"2019 novel coronavirus patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis","author":"Li","year":"2020","journal-title":"J Med Virol."},{"issue":"2","key":"10.1016\/j.mehy.2020.109776_b0045","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00388.2009","article-title":"Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist","volume":"298","author":"Kanda","year":"2010","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"10.1016\/j.mehy.2020.109776_b0050","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054\u20131062. doi:10.1016\/S0140-6736(20)30566-3.","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"10.1016\/j.mehy.2020.109776_b0055","doi-asserted-by":"crossref","unstructured":"Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 15;395 (10223):514-523. doi:10.1016\/S0140-6736(20)30154-9.","DOI":"10.1016\/S0140-6736(20)30154-9"},{"key":"10.1016\/j.mehy.2020.109776_b0060","article-title":"Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease","author":"Liu","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci."},{"issue":"10223","key":"10.1016\/j.mehy.2020.109776_b0070","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10229","key":"10.1016\/j.mehy.2020.109776_b0075","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.mehy.2020.109776_b0080","unstructured":"Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Feb 13, 2020. http:\/\/www.chictr.org.cn\/ showprojen.aspx?proj=49409 (accessed March 6, 2020)."},{"key":"10.1016\/j.mehy.2020.109776_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19","author":"Gao","year":"2020","journal-title":"J Med Virol."},{"key":"10.1016\/j.mehy.2020.109776_b0090","doi-asserted-by":"crossref","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-Mediated inflammatory responses: from mechanisms to potential therapeutic tools","author":"Fu","year":"2020","journal-title":"Virol Sin."},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0095","first-page":"203","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.mehy.2020.109776_b0100","doi-asserted-by":"crossref","first-page":"101642","DOI":"10.1016\/j.tmaid.2020.101642","article-title":"Sars-Cov-2: Underestimated damage to nervous system","author":"Zhou","year":"2020","journal-title":"Travel Med Infect Dis"},{"issue":"8","key":"10.1016\/j.mehy.2020.109776_b0105","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/444461","article-title":"Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis","volume":"41","author":"Xu","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mehy.2020.109776_b0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","article-title":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China","volume":"22","author":"Yu","year":"2020","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.20050828","article-title":"Multiple organ infection and the pathogenesis of SARS","volume":"202","author":"Gu","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2020.109776_b0120","article-title":"The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.mehy.2020.109776_b0125","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2020.109776_b0130","doi-asserted-by":"crossref","unstructured":"Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print, 2020 Mar 26].Clin Infect Dis. 2020;ciaa330. doi:10.1093\/cid\/ciaa330.","DOI":"10.1093\/cid\/ciaa330"},{"issue":"1","key":"10.1016\/j.mehy.2020.109776_b0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4149\/av_2018_103","article-title":"Highlighting the 'blood-nerve barrier' in virology research","volume":"62","author":"Mori","year":"2018","journal-title":"Acta Virol"},{"issue":"15","key":"10.1016\/j.mehy.2020.109776_b0140","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1128\/JVI.00737-08","article-title":"Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2","volume":"82","author":"Netland","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.109776_b0145","doi-asserted-by":"crossref","unstructured":"Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China [published online ahead of print, 2020 Mar 25]. Clin Immunol. 2020;108393. doi:10.1016\/j.clim.2020.108393.","DOI":"10.1016\/j.clim.2020.108393"},{"issue":"4","key":"10.1016\/j.mehy.2020.109776_b0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1753-0407.13027","article-title":"Diabetes and COVID-19","volume":"12","author":"Bloomgarden","year":"2020","journal-title":"J Diabetes"},{"key":"10.1016\/j.mehy.2020.109776_b0155","doi-asserted-by":"crossref","unstructured":"Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic [published online ahead of print, 2020 Mar 10]. Diabetes Metab Syndr. 2020;14(3):211\u2013212. doi:10.1016\/j.dsx.2020.03.002.","DOI":"10.1016\/j.dsx.2020.03.002"},{"key":"10.1016\/j.mehy.2020.109776_b0160","doi-asserted-by":"crossref","unstructured":"Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors [published online ahead of print, 2020 Mar 26]. Immunotherapy. 2020;10.2217\/imt-2020-0067. doi:10.2217\/imt-2020-0067.","DOI":"10.2217\/imt-2020-0067"},{"issue":"12","key":"10.1016\/j.mehy.2020.109776_b0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the Forgotten Diabetes Medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.mehy.2020.109776_b0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes","volume":"105","author":"Esser","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.mehy.2020.109776_b0175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrendo.2014.29","article-title":"Insulin resistance and hyperglycaemia in cardiovascular disease development","volume":"10","author":"Laakso","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.mehy.2020.109776_b0180","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2016.06.028","article-title":"Adiponectin, TNF-\u03b1 and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"86","author":"Liu","year":"2016","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.mehy.2020.109776_b0185","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/db16-0152","article-title":"Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture","volume":"65","author":"King","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0190","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/193229681000400326","article-title":"High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone","volume":"4","author":"Pf\u00fctzner","year":"2010","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.mehy.2020.109776_b0195","article-title":"Role of adipocyte mitochondria in inflammation, lipemia and insulin sensitivity in humans: effects of pioglitazone treatment","author":"Xie","year":"2017","journal-title":"Int J Obes (Lond)"},{"issue":"12","key":"10.1016\/j.mehy.2020.109776_b0200","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/ATVBAHA.108.175687","article-title":"Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance","volume":"28","author":"Zhang","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.mehy.2020.109776_b0205","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5414\/CP202339","article-title":"Pioglitazone inhibits the secretion of proinflammatory cytokines and chemokines in astrocytes stimulated with lipopolysaccharide","volume":"53","author":"Qiu","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1\u20133","key":"10.1016\/j.mehy.2020.109776_b0210","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2012.02.027","article-title":"Reduction of renal lipid content and proteinuria by a PPAR-\u03b3 agonist in a rat model of angiotensin II-induced hypertension","volume":"682","author":"Sakamoto","year":"2012","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109776_b0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jss.2014.03.007","article-title":"Pioglitazone attenuates lung injury by modulating adipose inflammation","volume":"189","author":"Kutsukake","year":"2014","journal-title":"J Surg Res."},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000168676","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis","volume":"77","author":"Aoki","year":"2009","journal-title":"Respiration."},{"key":"10.1016\/j.mehy.2020.109776_b0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1465-9921-6-112","article-title":"The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis","volume":"6","author":"Barbarin","year":"2005","journal-title":"Respir Res."},{"issue":"2","key":"10.1016\/j.mehy.2020.109776_b0230","first-page":"49","article-title":"PPAR-\u03b3 agonists for the treatment of major depression: a review","volume":"50","author":"Colle","year":"2017","journal-title":"Pharmacopsychiatry."},{"issue":"1","key":"10.1016\/j.mehy.2020.109776_b0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13543784.2017.1265504","article-title":"Pioglitazone for the treatment of Alzheimer's disease","volume":"26","author":"Galimberti","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.mehy.2020.109776_b0240","article-title":"Do PPAR-Gamma agonists have a future in parkinson's disease therapy?","volume":"2011","author":"Carta","year":"2011","journal-title":"Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.mehy.2020.109776_b0245","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/1389450111314070004","article-title":"PPAR-\u03b3: therapeutic prospects in Parkinson's disease","volume":"14","author":"Carta","year":"2013","journal-title":"Curr Drug Targets"},{"issue":"4","key":"10.1016\/j.mehy.2020.109776_b0250","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3233\/JPD-150666","article-title":"NINDS NET-PD Investigators. Peripheral biomarkers of parkinson's disease progression and pioglitazone effects","volume":"5","author":"Simon","year":"2015","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.mehy.2020.109776_b0255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12974-017-0957-8","article-title":"Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation","volume":"14","author":"Omeragic","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.mehy.2020.109776_b0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2017.03.021","article-title":"Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery","volume":"293","author":"Patel","year":"2017","journal-title":"Exp Neurol"},{"issue":"6","key":"10.1016\/j.mehy.2020.109776_b0265","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.brainresbull.2012.02.001","article-title":"Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide","volume":"87","author":"Shafaroodi","year":"2012","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0270","doi-asserted-by":"crossref","first-page":"F600","DOI":"10.1152\/ajprenal.00289.2005","article-title":"Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy","volume":"290","author":"Agarwal","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109776_b0275","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pupt.2008.11.011","article-title":"Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs","volume":"22","author":"Sharma","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.mehy.2020.109776_b0280","doi-asserted-by":"crossref","unstructured":"Guan WJ, Ni ZY, Hu Y et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056\/NEJMoa2002032.","DOI":"10.1056\/NEJMoa2002032"},{"issue":"4","key":"10.1016\/j.mehy.2020.109776_b0285","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3132\/dvdr.2008.043","article-title":"Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk","volume":"5","author":"Forst","year":"2008","journal-title":"Diab Vasc Dis Res"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720306186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720306186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:23:39Z","timestamp":1759692219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720306186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":57,"alternative-id":["S0306987720306186"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109776","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109776"}}